Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Investigations on Novel Gene Variants Associated with Longterm Response to Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia: Implication in TKI-Cessation Clinical Trails

Zafar Iqbal, BSc, MSc, PhD, Muhammad Absar, BSc, MSc, PhD, Abid Jameel, MD PhD, Tanveer Akhtar, PhD, Sulman Basit, PhDMSc, Aamer Mahmood, PhD, Aamir Aleem, MBBS FRCP, Nawaf Alanazi, MBBS FRCPC, Ullah Anhar, Naila Batool Khalid, Sibtain Afzal, Jamil Amjad Hashmi, Afia M Akram, PhD, Khushnooda Ramzan, PhD, Mahmood Rasool, Muhammad Hasaan Aziz, Muhammad Farooq Sabar, PhD, Mudassar Iqbal, MDMS, Ahmad Mukhtar Khalid, PhD

Blood (2019) 134 (Supplement_1): 2939.

https://doi.org/10.1182/blood-2019-125518

Published: 2019

Journal Articles

BCR-ABL Kinase Domain Mutations Exist in Few Imatinib Treated Chronic Myeloid Leukemia (CML) Patients Exhibiting Stable Cytogenetic and Hematologic Responses

Afia Muhammad Akram, PhD, Tanveer Akhtar, PhD, Asma Chaudhary, Muhammad Mudassar Shahzad, Ahmad Mukhtar Khalid, PhD, Nadia Sajid, MBBS, FCPS, Muhammad Farooq Sabar, PhD, Zafar Iqbal, BSc, MSc, PhD

Blood (2018) 132 (Supplement 1): 5427.

https://doi.org/10.1182/blood-2018-99-111757

Published: 2018

Journal Articles

Brief Research Report: Novel Compound BCR-ABL Mutations in Late Chronic Phase Imatinib Sensitive CML Patients Are Associated with Progression to Advance Disease Phase

Zafar Iqbal, MPhil PhDPost-doc., Afia Muhammad Akram, Tanveer Akhtar, PhD, Aamer Aleem, MBBS FRCP, Muhammad Farooq Sabar, PhD, Zeba Aziz, MD MBBS, Nadia Sajid, Mahmood Rasool, PhD, Muhammad Asif, Mehmood Husssain Qazi, PhD, Saleh Oraibi, PhD, Ammara T Gill, MBBS ABIM, Khalid Al Jamaan, MDFRCPC, Mudassar Iqbal, MDMS, Ahmad Mukhtar Khalid

Blood (2016) 128 (22): 3089.

https://doi.org/10.1182/blood.V128.22.3089.3089

Published: 2016

Journal Articles

Detection of Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a Novel K245N Mutation Associated with Primary Nilotinib Resistance By Employing a Newly Developed Cost Effective BCR-ABL Sequencing Protocol

Blood (2014) 124 (21): 1810.

https://doi.org/10.1182/blood.V124.21.1810.1810

Published: 2014

Journal Articles

High Frequency Of BCR-ABL/t(22;9) Translocation As Detected By RT-PCR and Interphase FISH In Pediatric B-Cell ALL Patients Identifies The Need For Immediate Inclusion Of Tyrosine Kinase Inhibitors In Pediatric ALL Treatment Protocols

Zafar Iqbal, MPhil PhD Post-doctorate, Tashfin Awan, MSc PhD, Tanveer Akhtar, MSc, PhD, Aleem Aamer, MBBS MRCP FRCPath, Noreen Sabir, MSc PhD, Muhammad Absar, MSc, Iqbal Mudassar, MD MS, Ahmad Mukhtar Khalid, MSc, PhD, Giuseppe Saglio, MD, Mahmood Rasool, Akhtar Hussain, BS MPhil

Blood (2013) 122 (21): 3908.

https://doi.org/10.1182/blood.V122.21.3908.3908

Published: 2013

Journal Articles

BCR-ABL Splice Variants In Three Phases Of CML: Association With Disease Biology and Response To Imatinib

Iqbal Zafar, MPhil PhD Postdoctorate, Saba Shahzadi, Tanveer Akhtar, MSc, PhD, Aleem Aamer, MBBS MRCP FRCPath, Ahmad Mukhtar Khalid, MSc, PhD, Iqbal Mudassar, MD MS

Blood (2013) 122 (21): 5191.

https://doi.org/10.1182/blood.V122.21.5191.5191

Published: 2013

Journal Articles

Presence of Prior-to-Treatment BCR-ABL Mutations In CD34+CD38- Stem Cells of Newly Diagnosed Chronic Phase CML Patients and Their Correlation with Imatinib Resistance: Implications of Cancer Pharmacogenomics and Pre-Therapeutic Genetic Testing In Personalized Treatment of BCR-ABL+ Leukemia

Zafar Iqbal, BSc, MSc, MPhil, PhD, Mudassar Iqbal, MD, Tanveer Akhtar, MSc, PhD, Mubashar Iqbal Naqvi, BS(CS), Ammara H Tahir, MBBS, Tariq Jameel Gill, MBBS, Muhammad Naeem Abbas, MLT, Abid Jamil, MBBS, PhD, Abid Sohail Taj, MBBS, PhD, Dr Abd-Al-Qayyum, MD, Najeeb ur-Rehman, BS, (Engg), Muhammad Ferhan, MSc, MPhil, Ijaz Hussain Shah, MBBS, FCPS, Muhammad Khalid, MBBS, FCPS, Weng Xian Qin, BSc(MLT), MS, Ahmad Mukhtar Khalid, MSc, PhD, Mahwish Khan, Aamer Aleem, MD, Shahid Mahmood Baig, MPhil, PhD

Blood (2010) 116 (21): 2278.

https://doi.org/10.1182/blood.V116.21.2278.2278

Published: 2010

NARROW

Investigations on Novel Gene Variants Associated with Longterm Response to Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia: Implication in TKI-Cessation Clinical Trails

BCR-ABL Kinase Domain Mutations Exist in Few Imatinib Treated Chronic Myeloid Leukemia (CML) Patients Exhibiting Stable Cytogenetic and Hematologic Responses

Brief Research Report: Novel Compound BCR-ABL Mutations in Late Chronic Phase Imatinib Sensitive CML Patients Are Associated with Progression to Advance Disease Phase

Detection of Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a Novel K245N Mutation Associated with Primary Nilotinib Resistance By Employing a Newly Developed Cost Effective BCR-ABL Sequencing Protocol

High Frequency Of BCR-ABL/t(22;9) Translocation As Detected By RT-PCR and Interphase FISH In Pediatric B-Cell ALL Patients Identifies The Need For Immediate Inclusion Of Tyrosine Kinase Inhibitors In Pediatric ALL Treatment Protocols

BCR-ABL Splice Variants In Three Phases Of CML: Association With Disease Biology and Response To Imatinib

Presence of Prior-to-Treatment BCR-ABL Mutations In CD34+CD38- Stem Cells of Newly Diagnosed Chronic Phase CML Patients and Their Correlation with Imatinib Resistance: Implications of Cancer Pharmacogenomics and Pre-Therapeutic Genetic Testing In Personalized Treatment of BCR-ABL+ Leukemia

Email alerts

ASH Publications

American Society of Hematology

Investigations on Novel Gene Variants Associated with Longterm Response to Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia: Implication in TKI-Cessation Clinical Trails

BCR-ABL Kinase Domain Mutations Exist in Few Imatinib Treated Chronic Myeloid Leukemia (CML) Patients Exhibiting Stable Cytogenetic and Hematologic Responses

Brief Research Report: Novel Compound BCR-ABL Mutations in Late Chronic Phase Imatinib Sensitive CML Patients Are Associated with Progression to Advance Disease Phase

Detection of Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a Novel K245N Mutation Associated with Primary Nilotinib Resistance By Employing a Newly Developed Cost Effective BCR-ABL Sequencing Protocol

High Frequency Of BCR-ABL/t(22;9) Translocation As Detected By RT-PCR and Interphase FISH In Pediatric B-Cell ALL Patients Identifies The Need For Immediate Inclusion Of Tyrosine Kinase Inhibitors In Pediatric ALL Treatment Protocols

BCR-ABL Splice Variants In Three Phases Of CML: Association With Disease Biology and Response To Imatinib

Presence of Prior-to-Treatment BCR-ABL Mutations In CD34+CD38- Stem Cells of Newly Diagnosed Chronic Phase CML Patients and Their Correlation with Imatinib Resistance: Implications of Cancer Pharmacogenomics and Pre-Therapeutic Genetic Testing In Personalized Treatment of BCR-ABL+ Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only